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Abstract Methylglyoxal (MG), an endogenous metabolite that 
increases in diabetes, is a common intermediate in nonenzymatic 
glycation (Maillard reaction) in vivo. Here we describe the 
immunochemical approach to the detection of MG adducts in 
proteins in vitro and in atherosclerotic lesions of human aorta in 
vivo. The reaction of protein (bovine serum albumin) with MG 
led to selective loss of arginine and lysine residues, accompanied 
by the formation of 5-methylimidazolone (^-(S-methylimidazo-
lon-2-yl)ornithine) and imidazolysine (l,3-di-lysino-4-methylimi-
dazole) derivatives, respectively. The anti-5-methylimidazolone 
antibody was prepared by immunizing rabbits with a MG-
keyhole limpet hemocyanin conjugate and purifying the serum on 
an affinity gel prepared by covalent attachment of the 5-
methylimidazolone derivative. The antibody cross-reacted with 
the proteins treated with not only MG but trioses, such as 
hydroxyacetone, dihydroxyacetone, and glyceraldehyde. The 
immunohistochemical analysis revealed that atherosclerotic 
lesions of human aorta contained 5-methylimidazolone deriva-
tives whose distributions were identical to those of advanced 
glycation end products (AGEs) detected by the anti-AGE 
antibody. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nonenzymatic glycation (Maillard reaction) is a complex 
series of reactions between reducing sugars and amino groups 
of proteins, which leads to browning, fluorescence, and cross-
linking of the proteins. The reaction is initiated with the re-
versible formation of a Schiff s base which undergoes a rear-
rangement to form a relatively stable Amadori product. The 
Amadori product further undergoes a series of reactions 
through dicarbonyl intermediates to form advanced glycation 
end products (AGEs) [1]. It has been shown that the forma-
tion of AGEs in vivo contributes to the pathophysiologies 
associated with aging and long-term complications of diabetes 
[2]. 
A number of sugars, in addition to glucose, are known to 
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form AGEs. Methylglyoxal (MG), among them, has recently 
received considerable attention as a mediator to form AGEs. 
MG is a biological metabolite formed by the nonenzymatic 
and enzymatic degradation of triose phosphate, dihydroxy-
acetone phosphate and glyceraldehyde-3-phosphate. Other 
sources include aminoacetone, hydroxyacetone, and products 
of threonine catabolism and acetone metabolism, respectively 
[3]. It has been reported that the concentration of MG in-
creases in cultured human red blood cells during hyperglyce-
mia [4]. Moreover, increased levels of MG are also found in 
blood from diabetic patients and in the lens of streptozotosin-
induced diabetic rats [5,6]. In vitro experiments have shown 
that MG undergoes a rapid reaction with proteins [7]. The 
reactions have been shown to occur even at physiological 
concentrations of MG [8] and form fluorescent products, 
characteristics of which resemble those occurring in proteins 
in aging and diabetes [9]. The high reactivity of MG with 
proteins and its relatively high concentration in the plasma 
[10] suggest that MG represents a common intermediate in 
the formation of AGEs in vivo. This assumption may be 
supported by the fact that macrophages have a specific recep-
tor for proteins modified by reaction with MG, as well as for 
glucose-derived AGEs [11]. 
In the present study, based on the observation that MG 
adducts of arginine and lysine were predominant products 
upon in vitro incubation of MG with protein, we raised anti-
bodies directed to the MG adducts and examined their pres-
ence in human atherosclerotic lesions in vivo. 
2. Materials and methods 
2.1. Materials 
Keyhole limpet hemocyanin (KLH) was obtained from Pierce. 
Horseradish peroxidase-linked anti-rabbit IgG immunoglobulin, and 
ECL (enhanced chemiluminescence) Western blotting detection re-
agents were obtained from Amersham. Affi-gel 102 was obtained 
from Bio-Rad. Methylglyoxal and other aldehydic compounds, JV™-
acetyl-L-lysine, A^-acetyl-L-arginine, and bovine serum albumin (BSA) 
were obtained from Sigma. 
2.2. The MG adducts of N°--acetylarginine and t^-acetyllysine 
The reaction mixture (10 ml) contained 100 mM MG and 100 mM 
amino acid derivative (A^-acetylarginine or A^-acetyllysine) in 50 mM 
sodium phosphate buffer (pH 7.2). After incubation for 3 days at 
37°C, the samples were applied to a Develosil ODS-HG-5 column 
(8X250 mm) (Nomura Chemicals) equilibrated in a solution of 10% 
methanol in 50 mM acetic acid and eluted at a flow rate of 1.0 ml/ 
min. The elution profiles were monitored by absorbance at 215 nm. 
Under these conditions, the major reaction products of MG with N-
acetylarginine and /V-acetyllysine were eluted at 9.0 min and 18.0 min, 
respectively. The chemical structure of the products was confirmed by 
fast atom bombardment-mass spectrometry (glycerol matrix) on a 
JEOL JMS-DX 705 mass spectrometer and nuclear magnetic reso-
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nance (NMR) on a Bruker ARX-400 spectrometer with tetramethyl-
silane as the internal standard [8,12]. The two major MG conjugates 
of arginine and lysine were identified as the 5-methylimidazolone (N°--
acetyl-Ar5-(5-methylimidazolon-2-yl)ornithine) and the imidazolysine 
(1 ,3-di-JV™-acetyllysino-4-methylimidazole) derivatives. 
2.3. Amino acid analysis 
Bovine serum albumin (1 mg/ml) in 50 mM sodium phosphate 
buffer (pH 7.2) was treated with 100 mM MG at 37°C. After incuba-
tion, the reaction mixtures were treated with 10% trichloroacetic acid. 
After centrifugation at lOOOOXg for 3 min, the proteins were hydro-
lyzed in vacuo with 6 M HC1 for 24 h at 105°C. The hydrolysates 
were concentrated and dissolved with 50 mM sodium phosphate buf-
fer (pH 7.2). The amino acid analysis was performed with a JEOL 
JLC-500 amino acid analyzer equipped with a JEOL LC30-DK20 
data analyzing system. 
2.4. Antibody preparations 
Polyclonal antiserum against MG-modified proteins was raised by 
immunizing a New Zealand White rabbit with KLH that had been 
treated with MG. In order to prepare a mono-specific antibody that 
specifically reacts with A^-(5-methylimidazolon-2-yl)ornithine or 1,3-
di-lysino-4-methylimidazole, the antiserum was treated with the affin-
ity gel (Affi-gel 102) which was derivatized by incubation of the gel 
slurry with A'°-acetyl-A'5-(5-methylimidazolon-2-yl)ornithine or 1,3-di-
A^-acetyllysino-4-methylimidazole in 0.1 M HEPES, pH 8.0, for 20 h 
at 4°C. The antiserum (2 ml) was loaded onto the column containing 
1 ml of affinity resin. Unbound proteins were removed by washing 
with 40 ml of 0.1 M HEPES buffer, pH 8.0, followed by 20 ml of 100 
mM NaCl, and the bound antibodies were eluted with 20 ml of 0.1 M 
glycine, pH 2.5. The eluate with glycine was immediately neutralized 
with 1 M Tris-HCl, pH 8.0, and stored at -80°C. 
2.5. Enzyme-linked immunosorbent assay (ELISA) 
A coating antigen was prepared by incubating 1 mg of BSA with 10 
mM aldehyde in 1 ml of 50 mM sodium phosphate buffer, pH 7.2, for 
24 h at 37°C. A 100-|!l aliquot of the antigen solution containing 0.4-
mg protein was added to each well of a 96-well microtiter plate and 
incubated for 20 h at 4°C. The antigen solution was then removed, 
and the plate was washed with Tris-buffered saline (TBS) containing 
10% Tween 20 (TBS/Tween). Each well was filled with 200 ul of Block 
Ace solution (100 mg/ml) for 30 min at 37°C. The primary antibody 
was then added to the wells at 100 ul/well of 1 |ig/ml solution for 3 h 
at 37°C or overnight at 4°C. The plate was then washed once with 
TBS/Tween. After discarding the supernatants and washing three 
times with TBS/Tween, 100 ul of a 5X 103 dilution of goat anti-rabbit 
IgG conjugated to horseradish peroxidase in TBS/Tween was added. 
After incubation for 1 h at 37°C, the supernatant was discarded, and 
the plates were washed three times with TBS/Tween. Enzyme-linked 
antibody bound to the well was revealed by adding 100 ul/well of 1,2-
phenylenediamine in 0.1 M citrate/phosphate buffer (pH 5.0) contain-
ing 0.003% H 2 0 2 . The reaction was terminated by the addition of 50 
JJ.1 of 2 M sulfuric acid, and the absorbance at 492 nm was read on a 
micro-ELISA plate reader. 
2.6. Imunoblot analysis 
The samples were treated with Laemmli sample buffer [13] for 3-5 
min at 100°C. The samples containing 10-jj.g protein were run on two 
12% SDS-PAGE slab gels. One gel was used for staining with Coo-
massie brilliant blue; the other was transblotted to nitrocellulose 
membranes, incubated with 2% BSA in TBS/Tween for blocking, 
washed, and treated with the primary antibody. This procedure was 
followed by the addition of horseradish peroxidase conjugated to goat 
anti-rabbit IgG immunoglobulin and ECL reagents. The bands were 
visualized by the exposure of the membranes to autoradiography film. 
2.7. Immunohistochemistry 
For indirect immunohistochemical staining, human arterial tissues 
obtained at autopsy were cut into 5-um sections, mounted on the 
slides coated with 3-aminopropyltriethoxy silane, deparaffined, rehy-
drated in distilled water, and then blocked in 4% skim milk for 2 h. 
The sections were incubated with either anti-5-methylimidazolone rab-
bit IgG (5 ug/ml), anti-imidazolysine rabbit IgG (5 Ug/ml), anti-AGE 
mouse monoclonal IgG (2 ug/ml) (6D12) (Wako Pure Chemicals) [14], 
or anti-CD68 mouse monoclonal IgG (2 ug/ml) (Dako) overnight in 
humid chambers at room temperature. The sections were washed and 
incubated with 1/100 diluted goat anti-rabbit or anti-mouse IgG con-
jugated with peroxidase (Dako) for 2 h at room temperature, followed 
by detection with 3,3'-diaminobenzidine solution containing 0.003% 
H2O2. Competition experiments to confirm the specificity of immu-
nostaining were also performed with anti-5-methylimidazolone IgG 
which was preincubated for 4 h at 37°C with an excess of free JV01-
acetyl-Af5-(5-methylimidazolon-2-yl)ornithine. Non-immune rabbit or 
mouse IgG was used as a negative control. 
3. Results 
3.1. Characterization of MG conjugates of arginine and lysine 
As consistent with the previous findings [15-17], the reac-
tion of protein (BSA) with M G resulted in selective loss of 
arginine and lysine residues. Accompanied with the irreversi-
ble modification of these amino acids, we detected two prod-
ucts (compounds 1 and 2), which were probably ascribed to 
the formation of MG-arginine and/or MG-lysine adducts, in 
the hydrolysates of MG-modified proteins (Fig. 1). To deter-
mine the structure of MG-modified arginine and lysine resi-
dues in proteins, the products formed by the reaction of M G 
with A^-acetylarginine or A^-acetyllysine were examined. Re-
action of JV-acetylarginine with M G generated a main product 
which was identified as the 5-methylimidazolone derivative, 
A'0!-acetyl-Ar8-(5-methylimidazolon-2-yl)ornithine (Fig. 2A), 
whose amino acid analysis gave a single peak identical to 
compound 1. Whereas the reaction of A^-acetyllysine with 
M G selectively generated the imidazolysine derivative, 1,3-
di-A /a-acetyllysino-4-methylimidazole (Fig. 2B), which gave 
compound 2 after acid-hydrolysis. As shown in Fig. 3, when 
BSA (1 mg/ml) was treated with 100 m M M G at 37°C, the 
level of both M G adducts reached a maximum within 24 h. 
15 20 25 30 35 40 45 
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Fig. 1. Detection of MG adducts by amino acid analysis. BSA (1 
mg/ml) in 50 mM sodium phosphate buffer (pH 7.2) was incubated 
in the absence (dotted line) and presence (solid line) of 100 mM 
MG at 37°C. After incubation, the reaction mixtures were treated 
with 10% trichloroacetic acid. After centrifugation at lOOOOXg for 
3 min, the proteins were hydrolyzed and subjected for automated 
amino acid analysis. The products 1 and 2 represent the newly 
formed MG adducts. 
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3.2. Antibodies raised against MG-treated KLH 
To detect the 5-methylimidazolone and imidazolysine deriv-
atives in biological tissue samples, antibodies were raised by 
immunizing rabbits with KLH directly modified with MG. 
Affinity purification using the 5-methylimidazolone or imida-
zolysine derivative as the ligand revealed that the anti-MG/ 
KLH antiserum contained antibody populations specific to 
these derivatives. The immunoblot analysis using the anti-5-
methylimidazolone IgG revealed that the immunoreactive ma-
terials were produced upon the reaction of BSA with MG 
(Fig. 4A), while the anti-imidazolysine IgG showed a weak 
immunoreactivity with the MG-modified BSA (data not 
shown). It was also revealed that the anti-5-methylimidazo-
lone IgG recognized not only the MG-modified proteins but 
the proteins treated with the trioses, including hydroxyace-
tone, dihydroxyacetone, and glyceraldehyde (Fig. 4B). 
3.3. Presence of 5-methylimidazolone derivative in the 
atherosclerotic lesions of human aorta 
It has been demonstrated that the rate of MG production 
increases during hyperglycemia [18]. Hence, in the present 
study, the presence of 5-methylimidazolone derivatives in 
vivo was evaluated in human atherosclerotic lesions by immu-
6 0 - A 
*M 
40 - \ 
c \ 
CD A 
O 
o 2 0 
E 
0 
O 
▲ 
0 1 14 
Incubation time (days) 
Fig. 3. Stoichiometry of loss of amino acids (arginine and lysine) 
and formation of MG adducts. Symbols: O, arginine; A, lysine; • . 
MG-arginine adduct (iV8-(5-methylimidazolon-2-yl)ornithine); ▲, 
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Fig. 2. HPLC profiles of the reaction mixtures of MG/iV-acetylargi-
nine (A) and MGA/V-acetyllysine (B). The reaction mixture (10 ml) 
contained 100 mM MG and 100 mM amino acid derivative (JV01-
acetylarginine or A^-acetyllysine) in 50 mM sodium phosphate buff-
er (pH 7.2). After incubation for 3 days at 37°C, the samples were 
applied to a Develosil ODS-HG-5 column (8x250 mm) equilibrated 
in a solution of 10% methanol in 50 mM acetic acid and eluted at a 
flow rate of 1.0 ml/min. Arrows indicate major products identified 
as A^-acetyl-JV5-(5-methylimidazolon-2-yl)ornithine (A) and 1,3-di-
A^-acetyllysino-4-methylimidazole (B). 
nohistochemistry. Massive deposits observed in the tissue 
were stained for the affinity-purified IgG to the 5-methylimi-
dazolone derivative (Fig. 5A). The deposits were surrounded 
with a number of mononuclear cells that were stained positive 
for CD68 (Fig. 5B), indicating that the infiltrating cells were 
tissue macrophages. It is of interest to note that the staining 
patterns of 5-methylimidazolone in these deposits were almost 
identical with those of the AGEs (Fig. 5C). Preadsorption of 
affinity-purified 5-methylimidazolone IgG by free A^-acetyl-
Af5-(5-methylimidazolon-2-yl)ornithine abolished the immu-
nostaining (Fig. 5D), indicating the specific reactivity of the 
antibody with epitopes. Non-immune rabbit or mouse IgG 
gave no immunostaining pattern. These results suggest that 
MG forms adducts with arginine and accumulates in the athe-
rosclerotic lesions, although the physiological significance of 
the formation of MG adducts, most importantly whether or 
not they have specific atherogenic properties, remains to be 
established. 
4. Discussion 
As previously reported [15-17], arginine and lysine residues 
represented major targets of MG in proteins, which resulted 
in irreversible modification of these amino acids. We demon-
strated that the irreversible modification of arginine and lysine 
by MG was partially ascribed to the formation of 5-methyl-
imidazolone and imidazolysine derivatives, respectively (Figs. 
1-3). To detect these MG adducts in biological tissue samples, 
immunochemical procedures using a specific antibody to the 
adducts were made. The affinity purification using the 5-meth-
ylimidazolone derivative as the ligand enabled to separate 
antibody populations specific to these derivatives from the 
antiserum. Using this antibody, we demonstrated for the first 
time the formation of 5-methylimidazolone derivatives in 
vivo. The data suggested that the formation of MG followed 
by the irreversible modification of proteins was associated 
with the development of atherosclerosis. Although the forma-
tion of 5-methylimidazolone in other tissues remains to be 
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Fig. 4. Immunoreactivity of anti-5-methylimidazolone IgG with modified proteins. (A) Immunoblot analysis of BSA treated with MG. BSA (1 
mg/ml) in 50 mM sodium phosphate buffer (pH 7.2) was incubated with 10 mM MG at 37°C. Formation of MG adducts in the protein was 
determined by immunoblot analysis using the affinity-purified anti-5-methylimidazolone IgG. (B) ELISA analysis of BSA treated with aldehydic 
compounds. A coating antigen for ELISA was prepared by incubating 1 mg of BSA with 10 mM aldehydic compound in 1 ml of 50 mM so-
dium phosphate buffer, pH 7.2, for 24 h at 37°C. 
established, this is expected to be shown in kidney, lens, and 
plasma proteins in diabetes mellitus, commensurate with the 
increase in MG in the tissue and blood concentration [4-6]. 
Lo et al. [8] have reported that the reaction of MG with 
arginine residues proceeds via the reversible formation of a 
glycosylamine and a dihydroxyimidazolidine, with slow con-
version to form a fluorescent imidazolone derivative. The for-
mation of imidazolone has been suggested to involve the 
spontaneous autoxidation of the intermediate 1,5-dihydroxy-
imidazolone. This and the fact [19] that the reaction of MG 
with amino acids generates free radicals imply that MG pro-
duction may be closely associated with oxidative stress. We 
have observed that, in human atherosclerotic lesions, the im-
munoreactive materials with the affinity-purified anti-5-meth-
ylimidazolone IgG colocalized with those detected with the 
antibody to the modified proteins with lipid peroxidation 
products, such as 4-hydroxy-2-nonenal and malondialdehyde 
(T. Miyata, Y. Yasuda and K. Uchida, unpublished observa-
tion). The importance of these lipid peroxidation-derived al-
dehydes has been implicated in the pathogenesis of numerous 
diseases, including atherosclerosis [20], cancer [21], Parkin-
son's disease [22], and Alzheimer disease [23,24], leading to 
the assumption that MG represents one of the primary sour-
ces of oxidative damage to protein in complex biological ma-
trices. 
It has been suggested that the imidazolones represent com-
mon structures in advanced glycation reactions [25]. In vitro 
glycation of proteins in fact generates an imidazolone deriva-
tive, Ar5-(5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl)ornithine 
[26]. The previous finding [11] that a macrophage receptor for 
MG-modified proteins recognizes glucose-modified proteins 
also suggests the possibility that the imidazolones are formed 
commonly as AGEs. The observation (Fig. 4B) that the anti-
5-methylimidazolone IgG cross-reacted with proteins that had 
been treated with trioses, such as hydroxyacetone, dihydroxy-
acetone, and giyceraldehyde, suggested that these compounds 
produced similar immunoreactive 5-methylimidazolone deriv-
atives in the protein to those generated in the MG-modified 
protein. In fact, proteins modified with dihydroxyacetone pro-
duce a derivative with identical fluorescence characteristics to 
MG-modified proteins [9]. Alternatively, they may produce 
MG during incubations, leading to the formation of MG-
modified proteins. This may be supported by the previous 
observations that triose phosphates such as glyceraldehyde-
3-phosphate and dihydroxyacetonephosphate degrade to 
MG [27,28]. Other dicarbonyl intermediates such as 3-deoxy-
glucosone could also form imidazolones [29]; however, the 
anti-5-methylimidazolone IgG scarcely cross-reacted with the 
protein treated with 3-deoxyglucosone (Fig. 4B). 
The immunohistochemical analysis using the antibody to 5-
methylimidazolone revealed that atherosclerotic lesions con-
tained epitopes in the granular cytoplasmic elements of foam 
cells (Fig. 5). Westwood et al. [11] have reported that both 
MG-modified proteins and glucose-derived AGEs bind to a 
common receptor in macrophages. The intracellular granular 
staining observed in atherosclerotic lesions may, therefore, 
represent the presence of MG-derived AGEs that had already 
been taken up by macrophages and are present within the cell 
in cytoplasmic organelles. Recently, one of the major epitopes 
of the anti-AGE antibody has been identified as A^-(carboxy-
methyl)lysine (CML) which is formed upon the reaction of 
lysine residues with glyoxal generated during the glycation 
reaction. In addition, CML has also been reported as a prod-
uct of lipid peroxidation [30]: a mechanism has been proposed 
in which the metal-catalyzed oxidation of polyunsaturated 
fatty acids in the presence of protein leads to the formation 
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Fig. 5. Immunohistochemical detection of 5-methylimidazolone derivatives and AGEs in fatty streak lesions of arterial tissue. Arterial tissue 
specimen from a 69-year-old male with atherosclerosis was immunostained for 5-methylimidazolone (A and D), CD68 (B), or AGEs (C). For a 
competitive experiment, anti-5-methylimidazolone IgG preincubated with an excess of iVa-acetyl-Ar5-(5-methylimidazolon-2-yl)ornithine was used 
(D). The nuclei were counterstained with Meyer's hematoxylin. The staining for 5-methylimidazolone and AGEs was positive in fatty streak le-
sions. A-D, X200. 
of glyoxal, an intermediate formed during lipid peroxidations, deposits were almost identical with those of the AGEs (Fig. 
reacting with lysine residues to generate CML. The observa- 5C) suggested that dicarbonyl intermediates, including MG 
tion that the staining patterns of 5-methylimidazolone in these and glyoxal, play an important role in the formation of arte-
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rial foam cells and contribute to the development of athero-
sclerosis. 
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